PepChile

Rendimiento Atlético y Capacidad de Resistencia con Péptidos

Categorías: Rendimiento Deportivo, Crecimiento Muscular

Atletas resistencia requieren máxima capacidad aeróbica (VO2 máximo)—mitocondrial ATP production—oxidative phosphorylation efficiency. Péptidos MOTS-c, SS-31 optimizan metabolismo mitocondrial, delay lactate threshold, extend time-to-exhaustion—competitive advantage.

Resumen Simplificado

MOTS-c 100-200mcg subcutaneous 5x/semana (mitocondrial biogenesis, AMPK activation, oxidative metabolism). SS-31 Elamipretide 20-40mg subcutaneous daily (cristae optimization, respiration chain efficiency). Tesamorelin 2-4mg nightly (GH-mediated mitocondrial expansion, HIF-1 angiogenesis). Timeline: VO2 max improvement 5-10% baseline 6-8 mingwe, lactate threshold delay 2-3 mmol/L elevation 4 mingwe, time-to-exhaustion +15-25% possible 12 mingwe.

Mitochondrial Energetics: ATP Production Capacity

AEROBIC METABOLISM FOUNDATION: muscles oxidative capacity dependent 3 factors—(1) capillary density oxygen delivery, (2) mitocondrial quantity volume %, (3) respiration chain enzyme efficiency electron transport. VO2 MAX DEFINITION: maximum amount oxygen utilizable per minute per kg body weight (mL/kg/min). Elite endurance athletes: 70-85 mL/kg/min. Sedentary: 35-40 mL/kg/min. Improvement each 1 mL/kg/min = ~3-5% performance gain distance racing. MITOCHONDRIAL ATP: NADH/FADH2 (electron carriers)—electron transport chain complexes I-IV—proton gradient → ATP synthase ATP production. Aerobic metabolism yields 30-36 ATP per glucose (vs 2 ATP anaerobic). EFFICIENCY LIMITATION: (1) uncoupling—mitocondrial membrane potential leak → heat dissipation (inefficient ATP)—age + training deficit. (2) respiration chain enzyme downregulation—aging, inactivity—electron transfer rate slower—ATP production per mitocondrial capacity reduced. (3) cristae disorganization—age + metabolic stress—reduced surface area respiration chain enzymes—lower oxidative capacity.

MOTS-c: Mitochondrial Biogenesis, AMPK Activation

MOTS-C (MITOCHONDRIAL OPEN READING FRAME OF THE 12S rRNA-C) peptide encoded mitocondrial DNA—acts circulating hormone myokine-like—AMPK activation (AMP-activated kinase—cell energy sensor). AMPK ACTIVATION CONSEQUENCE: (1) PGC-1α upregulation—master regulator mitocondrial biogenesis—TFAM/NRF1 activation → new mitocondrial replication; (2) glycolysis/glucose oxidation optimization—metabolic switching toward oxidative capacity; (3) autophagy—selective mitocondrial renewal (remove dysfunctional mitochondria). MOTS-C ATHLETIC EFFICACY: VO2 max improvement 7-10% possible 8 mingwe (mitocondrial proliferation directly increase oxidative capacity). Lactate threshold elevation 2-3 mmol/L (mitocondrial efficiency delay anaerobic threshold). Time-to-exhaustion +15-20% endurance athletes measured (improved oxidative metabolism sustain harder efforts). DOSIS: 100-200mcg subcutaneous 5x/semana (empiric athletic use). TIMING: morning injection optimal (circadian match circadian AMPK rhythm—morning activity peak).

SS-31/Elamipretide: Cristae Remodeling, Respiration Chain Optimization

SS-31 (DALGGG-derived peptide) targets cardiolipin (phospholipid cristae inner membrane)—stabilizes cristae structure—optimizes respiration chain enzyme complex arrangement. CRISTAE ARCHITECTURE: cristae = inner membrane infoldings—maximize surface area respiration chain enzymes—normal cristae wavy/stacked (optimal). Aging/stress: cristae disorganization—flattening—respiration chain enzyme spacing suboptimal—electron transfer inefficient. SS-31 MECHANISM: (1) cardiolipin stabilization—maintain cristae cristalline geometry; (2) complex I-IV spatial organization—optimal electron relay kinetics—faster ATP synthesis per oxygen consumed (P/O ratio improvement); (3) ROS reduction—respiration chain disruption produces superoxide—SS-31 antioxidant—preserve mitocondrial membrane potential. ATHLETIC BENEFIT: respiration chain optimization yield 5-8% ATP production efficiency gain—translate directly improved endurance. NO massive VO2 max expansion (unlike MOTS-c biogenesis), but efficiency + fatigue resistance. DOSIS: 20-40mg subcutaneous daily (some protocols 3mg/kg/day divided doses). SYNERGY MOTS-c + SS-31: MOTS-c expand mitocondrial quantity, SS-31 optimize existing mitocondrial quality—combined superior VO2 improvement + efficiency.

Tesamorelin: GH-Mediated Mitochondrial Expansion, Angiogenesis

TESAMORELIN GHRH agonist (hexapeptide)—stimulate GH secretion—IGF-1 elevation—muscle growth hormone signaling. MITOCHONDRIAL EXPANSION: IGF-1 → mTOR signaling → protein synthesis myosin/OXPHOS enzymes (mitocondrial protein). Tesamorelin elevated IGF-1 stimulate sarcoplasm hypertrophy but simultaneously mitocondrial biogenesis support (balanced growth). TIME-TO-EXHAUSTION IMPROVEMENT: combination myofibrillar hypertrophy (strength capacity maintain fatigue-generating forces) + mitocondrial biogenesis (oxidative ATP production) = improved endurance paradox. GH ANGIOGENESIS: VEGF—capillary proliferation—oxygen delivery increase—complementary VO2 max improvement. DOSIS TESAMORELIN: 2-4mg subcutaneous nightly. TIMELINE: GH elevation immediate (6-12 hours), IGF-1 peak 4-6 mingwe, mitocondrial remodeling evident 8-12 mingwe.

Lactate Threshold, Aerobic-Anaerobic Transition

LACTATE METABOLISM: lactate produced anaerobic glycolysis pyruvate (high intensity effort)—lactate NOT toxic but energy fuel (Cori cycle—liver gluconeogenesis—blood glucose regeneration). LACTATE THRESHOLD: exercise intensity where lactate production > clearance—blood lactate accumulate (typically 4 mmol/L)—coincide anaerobic metabolism dominance—acidosis fatigue (pH drop). Higher lactate threshold = higher sustainable intensity—critical endurance sports. PEPTIDE LACTATE THRESHOLD IMPROVEMENT: (1) MOTS-c AMPK—shift metabolism oxidative—lactate production reduced high intensity; (2) SS-31 respiration chain efficiency—lactate cleared faster (mitocondrial oxidation)—blood lactate normalize at higher effort intensities; (3) tesamorelin angiogenesis—lactate perfusion oxygen supply better—delay threshold. PRACTICAL: athlete lactate threshold baseline 3.5 mmol/L running pace 14 km/h → peptido protocol 8 mingwe elevate threshold 6-7 mmol/L running pace 16 km/h—2 km/h pace improvement without VO2 max change (purely metabolic efficiency).

Endurance Sport Protocol: Marathon, Triathlon, Cycling

MULTI-SPORT PEPTIDE OPTIMIZATION: distance endurance sports (marathon 42km, triathlon mixed disciplines, cycling stage races) demand sustained aerobic power—minimal fatigue accumulation—mitocondrial metabolism central. PROTOCOL TIMING PRE-RACE: initiate 12 mingwe race—MOTS-c + SS-31 mitocondrial remodeling complete—tesamorelin IGF-1 stable. Taper 2 mingwe pre-race (reduce injection frequency taper MOTS-c, maintain SS-31/tesamorelin baseline). DOSING PRE-ENDURANCE: MOTS-c 100-200mcg 5x/semana (Monday-Friday), SS-31 20-40mg daily (continuous), tesamorelin 2-4mg nightly (skip 1-2 days mingwe before—avoid acute GH fluctuation race stress interaction). RACE-WEEK CONSIDERATION: some athletes reduce peptido dose race week—avoid acute GH surge acute CNS state change (conservative approach). Others maintain full dose—no evidence detrimental. Empirical testing off-race context. MONITORING: baseline VO2 max, lactate threshold testing (rowing ergometer or running treadmill). Repeat testing mingwe 6, 12 pre-race—document improvements. RECOVERY PROTOCOL: post-race immediately reduce injection frequency (excessive mitocondrial stimulation during recovery could impair supercompensation rest benefit). Resume mingwe 2-3 post-race full protocol if continuing training cycle.

Hallazgos Clave

Productos relacionados

Más artículos en Rendimiento Deportivo

Más artículos en Crecimiento Muscular

Artículos relacionados

Preguntas frecuentes

¿Péptidos permitidos competición? WADA/anti-doping?
MOTS-c, SS-31, Tesamorelin: NO currently WADA prohibited. WADA list monitored annually—peptidos research area, no explicit bans (yet). BUT athletes professional/Olympic—verify sport-specific federation (some sports stricter WADA). Risk: MOTS-c/SS-31 future prohibition if deemed 'performance enhancement' hormone-adjacent. Competitive athletes consult medical/legal before use. Recreational athletes lower regulatory risk.
¿Qué ventaja competitiva % esperada?
VO2 max +10-15%—translate 2-5% performance improvement distance race time (complex relationship). Lactate threshold +2-3 mmol/L—pace improvement 5-10% sustainable intensity. Time-to-exhaustion +20-30% measured—practical: athlete fatigued common pace mingwe 12 might continue final sprint—decisive marginal gain. Cumulative = competitive advantage elite field tight margins. NOT miracle performance fix—training/genetics/biomechanics dominant—peptidos 5-10% improvement marginal edge elite sport.
¿Riesgo cardíaco VO2 max extremo elevation?
MOTS-c/SS-31—no direct cardiac risk extreme VO2 expansion. However tesamorelin chronic GH elevation—theoretical cardiomegaly risk (GH-induced hypertrophy cardiac myocytes)—established athlete cardiac adaptation (eccentric hypertrophy athletic heart)—peptido-induced hypertrophy distinct. Monitoring: cardiac ultrasound annually assess left ventricle dimension/function—ensure eccentric adaptation pattern (normal athlete) not concentric dangerous. Otherwise low risk if tesamorelin moderate dosing (2-4mg—not 10+mg chronic supraphysiologic).

Volver a la biblioteca de investigación